Investment received from Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket
Funding will be used to accelerate growth in operations and sales across the UK and USA
Cambridge, UK, 29 January 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that is has closed a $2 million (circa £1.5 million) investment round. The Company secured funding from several investors including Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket. The funds raised will be used to accelerate growth in operations and support sales of its Cyto-Mine® Single Cell Analysis System. Sphere Fluidics’ Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. It can process up to 40 million cells per day, and assesses and isolates those that produce a specific biologic to help streamline workflows and improve throughput in antibody discovery and cell line development. The Company will use the investment to expand operations and sales capabilities across the UK and USA and open a new US West Coast Sales Office. Frank F Craig PhD MBA, CEO, Sphere Fluidics, said: “We are pleased to see such a high level of interest in Sphere Fluidics and receive funding from several leading investors. We are making further investment in automating and streamlining our manufacturing processes across our product range to extend our offering and to deliver our high-quality standards and service to more researchers working in biotherapeutic discovery and cell line development across the UK and USA. We will be raising additional funds to expand these capabilities further.” Cyto-Mine will be on display in Washington, DC at SLAS 2019 from 2nd to 6th February 2019 (Booth #1655 and #1429). For more information about Sphere Fluidics and Cyto-Mine, please visit: https://spherefluidics.com/products/integrated-systems/cyto-mine/
Our CEO, Dr Frank F Craig, will be attending The British Private Equity & Venture Capital Association (BVCA) Sector Forum Series on Healthcare at The Royal Society in London on the 8th February 2019. The BVCA Sector Forum Series brings together a host of industry experts to discuss current trends, challenges and opportunities. Add the date to your diary to join us. www.bvca.co.uk/Calendar/Event-Details/DateId/1043
We are delighted to be sponsoring the next EBI-Sanger-Cambridge PhD Symposium (eSCAMPS) on 15 February 2019 at Jesus College. eSCAMPS is a free one-day symposium for postgraduate students interested in life sciences. Come along and speak with our R&D scientists to find out more about Sphere Fluidics and the cutting edge research that goes on behind the scenes! This year eSCAMPS are hosting some fantastic speakers including Prof. Donnelly, Prof. Donald, Dr. Yeo, Dr. van Schaik and Prof. Gero Miesenböck. Read more about the symposium and the speakers here : https://escamps.org/escamps19/speakers/
We have been voted as one of the most groundbreaking technologies of 2018 in the Medicine Maker Innovation Awards! The Medicine Maker Innovation Awards highlight the most groundbreaking drug development and manufacturing technologies released onto the market over the course of the year and we are honoured to have Cyto-Mine® nominated as one of the top 16 technologies showcased. The Medicine Maker is now looking for votes for which innovation out of the top 16 is truly the most innovative! We need support from our users and vendors to become the favourite in their online vote. Voting will close on February 28, 2019. Vote for Cyto-Mine® here: https://www.smartsurvey.co.uk/s/RN2OC/
PAA’s S-LAB micro-plate handling capability will be integrated with Sphere Fluidics’ Cyto-Mine Single Cell Analysis System
Cambridge and Farnborough, UK, 15 January 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leader in the industry for the design and manufacture of automated laboratory equipment, will collaborate to offer automated micro-plate handling capabilities for single cell analysis. PAA’s S-LAB™ plate handler will be integrated with Sphere Fluidics’ Cyto-Mine® Single Cell Analysis System to help increase throughput in antibody discovery and cell line development.
Sphere Fluidics’ Cyto-Mine is an automated platform which combines single cell screening, sorting, isolation and clone verification, alleviating the need for separate instruments. Its application programming interface (API), introduced as part of the updated Cyto-Mine Studio Software Suite in 2018, enables easy communication with PAA’s innovative S-LAB automated plate handler. The integration of micro-plate handling with the Cyto-Mine will help to reduce hands-on intervention to further streamline biopharmaceutical workflows.
Dr Frank Craig, CEO, Sphere Fluidics, commented: “Our Cyto-Mine is compatible with 96- and 384-well microtiter plates, providing a high-throughput platform for single cell analysis. By combining this with the easy-to-use automated plate handler from Peak Analysis and Automation we will be able to offer improved throughput capabilities to help reduce timelines in biotherapeutic discovery and cell-line development.” Dr Malcolm Crook, Technical Director, Peak Analysis and Automation, said: “Our small, affordable plate handler with the reliability of a robotic arm will offer users of Sphere Fluidics’ award-winning Cyto-Mine system a simple and flexible solution to further improve workflows and reduce costs associated with a more labor-intensive approach.”
Cyto-Mine will be on display in Washington, DC at SLAS 2019 from 2nd to 6th February 2019 (Booth #1655 and #1429). For further information about Sphere Fluidics and Cyto-Mine, please visit: https://spherefluidics.com/products/integrated-systems/cyto-mine/ For further information about PAA’s lab automation systems, please visit: https://www.paa-automation.com/products/automated-platehandlers/